JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway? Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. https://t.co/SvkcZwqzBo https://t.co/M3BkoF4amb

• https://bit.ly/39UlJHF

Metanalysis of 7 studies shows that oral anticoagulants need not be discontinued for joint injections or aspiration. Only pts w/ hemorrhage after 5427 procedures, over 32-yrs. INR values of 3 bleeding cases was 1.9, 2.3, and 3.4. https://t.co/pCxDqzXGHQ https://t.co/ExZkXSliFo

• https://bit.ly/3yh7A0E

Modest Benefits of Diet on Arthritis A EULAR taskforce reviewed the literature on the effects of diet and lifestyle behaviors in RMDs, and found little evidence suggesting dietary factors can substantially affect the outcomes in people with RMDs. https://t.co/D31l7dlq9v https://t.co/Kt80Yp74ro

• https://bit.ly/3nijrFg

#Leadership = serving your team, being the fall guy, getting group through crazy unnecessary beaurocracy, and loving something about each member of the group. Having their back, sacrificing for them. I can only strive to lead....

Treatment of pyoderma gangrenosum is clinically empiric. Full read ref w/ Graded Rx Recommendations: - 1st line: Steriods or Cyclosporin - Consider biologics: TNFi, IL-1, IL-12/23, IL-17, IL-23 - Others: MTX, MMF, AZA, Dap, colchic, thalidomide, IVIG https://t.co/uMJyfFzsRB https://t.co/vw4VqbjZWh

• https://bit.ly/3Oys5LK

Multinational recs. on Rx of JIA assoc. Uveitis: - Topical steroids are 1st line Rx - Systemic Rx if above fails or w/ poor prognosis or persistence - Options MTX, MMF then Humira EOW, then weekly ADA - Consider non-ETN TNFi's, then TCZ, ABA, JAKi or RTX https://t.co/ZfVeWf5sVg https://t.co/yu3to0LdEd

• https://bit.ly/3OpClpU

Podcast on Podcasting A tutorial on podcasting - what works and what does not. https://t.co/QINseXd6Z2 https://t.co/OFuVacgcfq

• https://bit.ly/3OpJOFi

Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (OR 1.12; 1.08–1.15), , w/ no effect of ozone. Results not changed by controlling for smoking. https://t.co/7BGBh9h0lf https://t.co/LcUo4Lxzgx

• https://bit.ly/3HNnanM

Axial PsA: Is it for Real? Dr. Janet Pope ( @Janetbirdope) presenting from EULAR 2022. https://t.co/0smaACel5k https://t.co/UJ3hi3rJlY

• https://bit.ly/3OHyOTh

Lupus Research Alliance’s has awarded the Lupus Insight Prize to Akiko Iwasaki, PhD (professor at Yale School of Medicine) for her research on the pathogenic role of retroviruses in lupus published in Journal of Experimental Medicine https://t.co/xmQjFLk63K https://t.co/68Ezlfk00j

• https://bit.ly/3HLqJuN

Lower Fx risk in PsA Rx w/ biologics? Review of 100 RCTs, 51,413 Pso & PsA pts; pts on bDMARDs had signif lower risk of major OP Fx (OR 0.34), hip Fx (OR 0.22) & OP non-vertebral Fx (OR 0.26). Fx risk not changed in RA, axSpA, SLE, IBD pts on biologics https://t.co/Acv1q1K5A9 https://t.co/dAaq2EsTDK

• https://bit.ly/3HNNT3q

RWE & Registries in Psoriatic Arthritis Dr. Alexis Ogdie presents RWE & Registries in Psoriatic Arthritis at the 2022 RheumNow Live meeting. https://t.co/zYcDrhgbNr https://t.co/s4Hv3ub9Av

• https://bit.ly/3HKPN4Y

Metanalysis of 7 studies shows that oral anticoagulants need not be discontinued for joint injections or aspiration. Only pts w/ hemorrhage after 5427 procedures, over 32-yrs. INR values of 3 bleeding cases was 1.9, 2.3, and 3.4. https://t.co/l130TsksVi https://t.co/OD7SSBuAS0

• https://bit.ly/3Nmhh2g